ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevalence of Lymphoma in IBD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00577538
Recruitment Status : Completed
First Posted : December 20, 2007
Last Update Posted : August 10, 2015
Sponsor:
Information provided by (Responsible Party):
Indiana University

Brief Summary:
Patients with inflammatory bowel disease (IBD) may be at increased risk of lymphoma. The majority of lymphomas in patients with IBD occur in areas of active inflammation. The relationship between IBD and lymphoproliferative disease is however unclear, since both chronic inflammation as well as medications used to treat IBD (especially immunosuppressives - Azathioprine or 6-MP - and anti-TNF alpha agents) have been associated with increased risk of lymphoma. We plan to study the association between IBD and lymphoma in a large, mixed, community based and referral population from the IBD database at Indiana University.

Condition or disease
Lymphoma Inflammatory Bowel Disease

Study Type : Observational
Actual Enrollment : 7 participants
Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Prevalence and Risk Factor for Lymphoproliferative Disease in Patients With Inflammatory Bowel Disease
Study Start Date : April 2006
Actual Primary Completion Date : October 2008
Actual Study Completion Date : October 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Group/Cohort
1
2




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients diagnosed with both Inflammatory bowel disease and lymphoma over the last 30 years.
Criteria

Inclusion Criteria:

  • Inflammatory Bowel disease
  • Lymphoma

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00577538


Locations
United States, Indiana
Indiana University Medical Center
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
Indiana University
Investigators
Principal Investigator: Michael V. Chiorean, M.D. Indiana University

Responsible Party: Indiana University
ClinicalTrials.gov Identifier: NCT00577538     History of Changes
Other Study ID Numbers: 060358
IRB# 0603-58
First Posted: December 20, 2007    Key Record Dates
Last Update Posted: August 10, 2015
Last Verified: August 2015

Additional relevant MeSH terms:
Lymphoma
Intestinal Diseases
Inflammatory Bowel Diseases
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Gastrointestinal Diseases
Digestive System Diseases
Gastroenteritis